Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen R Walsh

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
The Lancet. HIV|February 21, 2020
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)Kathryn E Stephenson, Frank Wegmann, Frank Tomaka, et al.
Vaccine|February 23, 2026
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trialsAaron Hudson, Scott Borgetti, Anne-Marie Rick, et al.
The Journal of Infectious Diseases|September 3, 2024
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 TrialsHolly Janes, Leigh H Fisher, Jia Jin Kee, et al.
Plos Medicine|May 23, 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trialsZoe Moodie, Stephen R Walsh, Fatima Laher, et al.
JAMA Network Open|May 28, 2025
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical TrialsLeah I B Andrews, M Elizabeth Halloran, Kathleen M Neuzil, et al.
JAMA Network Open|May 23, 2024
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized TrialsLeigh H Fisher, Jia Jin Kee, Albert Liu, et al.
Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087)Stephen R Walsh, Cynthia L Gay, Shelly T Karuna, et al.
The Journal of Clinical Investigation|February 14, 2023
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adultsKristen W Cohen, Andrew Fiore-Gartland, Stephen R Walsh, et al.
Medrxiv : the Preprint Server for Health Sciences|December 16, 2022
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccineGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
BMC Immunology|February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIVTariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
The Lancet. HIV|February 21, 2020
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)Kathryn E Stephenson, Frank Wegmann, Frank Tomaka, et al.
Vaccine|February 23, 2026
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trialsAaron Hudson, Scott Borgetti, Anne-Marie Rick, et al.
The Journal of Infectious Diseases|September 3, 2024
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 TrialsHolly Janes, Leigh H Fisher, Jia Jin Kee, et al.
Plos Medicine|May 23, 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trialsZoe Moodie, Stephen R Walsh, Fatima Laher, et al.
JAMA Network Open|May 28, 2025
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical TrialsLeah I B Andrews, M Elizabeth Halloran, Kathleen M Neuzil, et al.
JAMA Network Open|May 23, 2024
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized TrialsLeigh H Fisher, Jia Jin Kee, Albert Liu, et al.
Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087)Stephen R Walsh, Cynthia L Gay, Shelly T Karuna, et al.
The Journal of Clinical Investigation|February 14, 2023
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adultsKristen W Cohen, Andrew Fiore-Gartland, Stephen R Walsh, et al.
Medrxiv : the Preprint Server for Health Sciences|December 16, 2022
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccineGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
BMC Immunology|February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIVTariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
Pageof 8